Genuit Share Discussion Threads

[rambutan2] 02/4/2004 10:24

results and 1 for 1 rights issue. get reading.

[rambutan2] 01/4/2004 10:45

very little.

[canford cliffs] 01/4/2004 07:54

Max, how much is this gonna give GEN on the bottom line.....

[maxwellsdemon] 31/3/2004 00:17

Press Releases

The World's Biggest Race: Generics takes Hornby slot car racing into realms of global virtual reality
29 March 2004

Scalextric Sport World System, a combination of hardware and software that allows racers from all over the world to compete against each other via the Internet was launched at the London Toy Fair last month. This major new product is the result of an eighteen-month collaboration between The Generics Group (Generics), Hornby Plc and UK software company, Spike.

The PC hardware communicates with software developed by the Spike team and this will significantly upgrade the Scalextric slot car racing system by creating an incredible on-line racing experience.

This will include full 3D coverage, different race modes, data and enhancements. The Sport World System can operate either connected to the Internet or in standalone mode, thus combining the opportunities for a physical and a virtual experience. The revolutionary hardware developed by Generics consists of a control unit fitted with a LCD screen that allows racers to choose from one of nine race modes, from Arcade to Grand Prix.

It will also offer an unrivalled level of race management variables, including the ability to tune cars, accurate timing to 1/1000sec and accurate measurements of location and speed; as well as 3-D circuit design and variable race conditions such as pit-stop strategy and weather conditions.

The special Scalextric Internet server gives access to a world of on-line racing to suit all levels of ability. The website will integrate the position of all on-line racers on a single, virtual racetrack with detailed graphics of each car. The system allows integrated multi-player racing, team tournaments and permit spectators from around the world to follow the progress of any race with virtual coverage on screen.

Prior to the launch, Generics has been key in identifying the appropriate technologies, undertaking research and developing of new concepts to identifying production facilities and transfer manufacture in China. The launch represents a major landmark in an ongoing technology development programme undertaken by Generics and Hornby Plc.

Frank Martin, Chief Executive of Hornby Plc commented:

'The development of Scalextric Sport World confirms our commitment to enhancing the Scalextric racing experience. Our relationship with Generics has been instrumental in the development of this innovative challenge. Generics has demonstrated a real commitment to delivering real value to our business.

We are now confident that by combining interactive technology and actual track layouts, that we will start to develop an active community of keen Scalextric racers and enthusiasts, who are able to race against each other all over the world in virtual reality. We are confident that many existing Scalextric racers will upgrade to the new systems.'

[canford cliffs] 28/3/2004 20:27

and don't forget that they are currently claiming £1 million from the I/R, which should give plenty of cash for future projects......

[rambutan2] 28/3/2004 17:25

so, post 274 answered.
note that the building is worth more than the mkt cap.
here in full...

26 March 2004

The Generics Group AG

Completion of UK Headquarters Building

The Generics Group AG ('Generics' or the 'Company') is pleased to announce that
it has reached settlement in relation to the previously announced completion of
the construction of its flagship UK headquarters building at Harston Mill in
Cambridge. Generics has agreed, with the contractor employed to carry out the
building works, that the final account of the building works is £9.5m. Under the
terms of the settlement Generics will pay the outstanding £1.3m to the
contractor over the next three months. The land and building, which has been
shortlisted for the 2004 RIBA Awards for Architecture, was held in the balance
sheet at 30 September 2003 with a net book value of £14.6m.

In the Q3 results to 30 September 2003, announced on 4 December 2003, the
Chairman noted in the statement that 'the Company intends to raise further funds
for investment in the portfolio though an equity issue of up to approximately
£8m early in the New Year. Our principal shareholder, Catella AG, has indicated
to the board that it would subscribe £4m in such an issue'. The directors of
Generics confirm this remains the intention of both the Board and Catella.

[loss-leader] 27/3/2004 15:16

Generics Group AG said it reached settlement on costs
relating to the building of its UK headquarters and also reaffirmed plans to
raise up to 8 mln stg in a share issue.
The company said it agreed with the contractor thatthe final cost of the
work on the HQ building at Harston Mill in Cambridge will be 9.5 mln stg.
Generics will pay the outstanding 1.3 mln stg to the contractor over the next
three months.
Turning to the planned share issue, Generics said its principal shareholder
Catella AG still intends to subscribe for 4 mln stg in the fundraising.

..so it all comes down to the terms of the fundraising. I guess that Catella will not pay over the odds ..and presume we get the same deal. ll

[rambutan2] 24/3/2004 18:21

needlestick injury normally refers to the investors of the companies who try and launch safety devices! lets hope gens version has better luck.

wonder if theyve now got enough to avoid the fund raising? or are they aiming to launch it off the recent better news?

[maxwellsdemon] 24/3/2004 16:52

Safety syringeDeveloping a safety device to prevent syringe injuries

Needlestick injuries are a major cause of concern for health professionals worldwide as they can lead to infection or even be fatal. Generics recognised the potential for developing an inexpensive safety device to offer protection from injuries.

Working in consultation with a local NHS trust, we designed Autosheath, a simple one-piece casing which entirely covers the needle and can be used with existing syringes.

Autosheath ensures ease of use and safety throughout the entire injection procedure while its novel design barely increases the cost of each syringe. We have now patented the product concept.

[maxwellsdemon] 24/3/2004 16:43

Generics signs exclusive agreement in the battle to reduce the risk of needlestick injuries
24 March 2004
The Generics Group ('Generics'), the international technology and business consulting organisation, is pleased to announce that on 9 March 2004, it entered into an exclusive licence agreement with a major international diversified manufacturing and service company in respect of its Autosheath™ needlestick prevention technology.

The licence involves the immediate payment of an initial consideration of US$500,000 to Generics, together with additional payments over eight years, subject to the achievement of various technical and commercial milestones.

Generics will in addition provide technology development and support services from its Cambridge laboratories to enable the manufacturing and launch of the final product in an efficient and timely manner.

Generics' Autosheath™ technology represents a breakthrough in needlestick injury prevention. It is an inexpensive safety device that can be used with any standard low-cost syringe and the novel design offers protection throughout the whole injection procedure. The new technology is likely to provide a significant reduction in needlestick injuries to health care personnel caused by accidental handling of injection products.

The technology resulted from the continuous and wide ranging innovation strategy within the Generics Group which has led to a succession of key exploitation opportunities over many years.

Managing Director of Generics, Martin Frost said: "We are delighted to have entered into such a lucrative agreement; the global hypodermic syringe market is a multi-billion industry and we look forward to the successful commercial exploitation of this technology. In accordance with Generics' standard accounting policies for developments of this type, the Autosheath™ technology has nil asset value in the books, as a result of which the consideration will substantially represent profit to the Group. "

[maxwellsdemon] 13/3/2004 19:25

News item from IEE Review:
Scientists and engineers at the Generics Group near Cambridge, UK have harnessed the principles of the Whispering Gallery of St Paul's Cathedral to achieve a significant advance in high-frequency microwave measurement.

[canford cliffs] 12/3/2004 12:58

and don't forget they have a 6 figure tax refund still to be repaid which should help swell the coffers.....

[rambutan2] 12/3/2004 12:16

well, they are putting off that promised early year fund raising.
do they think that can get through without it?

re the above deal. i wonder what the future royalties deal is like?

[loss-leader] 12/3/2004 07:53

Generics announces the sale of one of its portfolio companies, Sensopad
Technologies Limited to TT electronics plc ("TT electronics") for an initial
cash consideration of #1.4 million together with future royalties. This is
expected to generate for Generics' 77.8% shareholding a profit of
#0.9million excluding future royalties.

Formed in April 2001 Sensopad has developed a number of leading edge
patented sensor technologies. These sensors have numerous applications in a
wide range of key sectors including automotive, domestic appliances,
industrial, consumer electronics and children's games.

Managing Director of Generics, Martin Frost said:"I am pleased to announce
the latest sale from our investment portfolio and look forward to the
successful commercial exploitation of the technology through TT electronics'
global market channel."

Generics is a leading integrated technology consulting, development and
investment organisation, with an international reputation for successfully
commercialising emerging science and technology. Generics invests in and
develops future technologies for use in a wide range of industries. Its key
areas of expertise include: engineering, materials, telecommunications, life
sciences, business innovation and electronics. Generics' facilities include
state-of-the-art laboratories and are located in Cambridge, Frankfurt,
Zurich, Switzerland and Stockholm and in Boston and Baltimore in the USA.

TT electronics is a focused, global electronics company supplying the
world's leading manufacturers in the automotive, telecommunications,
computing and industrial electronics markets. TT electronics' continuing
investment in modern manufacturing equipment and the development of new
technologies is based upon understanding its customers' needs and providing
solutions. Based in the UK the group has achieved a truly global reach. TT
electronics has established technical and manufacturing facilities in
strategic countries maintaining the successful formula of close liaison with
its customers in most major overseas markets.

This is a nice example of GEnerics doing the sort of thing that it said it was going to do. OK the price is not wonderful ..but it is a sign ..and will help tide them thro to profitability.

ll

[maxwellsdemon] 24/2/2004 14:01

Press ReleasesGenerics and BOC Edwards announce the delivery of a revolutionary pharmaceutical weighing technology to its first customer
17 February 2004
The Generics Group (Generics) and BOC Edwards Pharmaceutical Systems are delighted to announce the delivery, to a major US pharmaceutical company, of the first magnetic resonance (MR) check-weighing technology for a pharmaceutical packaging application.

The technology, licensed on a royalty basis by Generics, has been used by BOC Edwards Pharmaceutical Systems to successfully develop an innovative Non-Contact Check-Weighing system.

The in-line Non-Contact Check Weighing system is a major development to suit the FDA's new Process Analytical Technology initiative. It provides 100% protocolling and maximum feedback for any preceding filling system.

Generics' MR technology created the opportunity to provide an innovative and highly effective check-weighing solution for product filling lines. Traditional methods required samples to be removed from the production lines and weighed on precision balances, both before and after filling, a process that was time-consuming and resulted in inspection rates of only a few percent.

The technology makes it possible for check-weighing to be completed without removing samples from the line, resulting in a 100% inspection rate and considerable improvement in quality control, waste reduction and efficiency.

In BOC Edwards Pharmaceutical Systems first order, a Non-Contact Check-Weigher will be integrated into a pharmaceutical filling line designed to fill 2ml – 100ml vials at rates of up to 400 vials per minute, and will perform fill level verification on every single vial.

Dr Paul Stewart, Director of Technology in BOC Edwards said: "We are delighted to have worked with Generics on this revolutionary system. The order is of major importance to BOC Edwards; it demonstrates the success of this innovation in check-weighing, the most significant in over fifty years."

[rambutan2] 17/2/2004 17:06

nick, catella are part of the ikea empire and have a slightly offbeat, long-term investment philosophy. odds are that they wouldnt be persuaded.

re the funding. i would bet on it going ahead. remember that the management and staff hold quite a few shares and so might want to be involved? (please note that this is just my thoughts and i have no contact with the co or anyone in cambridge. im sure that some local cambridge folk ie pdt thread, bprg thread, might have heard whispers)

regards
rambutan

[nick2412] 17/2/2004 16:49

rambutan2 - thanks for that. So it would be a question then if the likes of MMG's David Best or any other interested party were persuasive enough with Catella AG. I would have thought Catella AG would be disappointed with current managements performance but I have only followed this share from a distance until buying in recently. If they opt for a funding I wonder if it will be a placing or whether all shareholders will be allowed to participate.

[rambutan2] 17/2/2004 15:35

shirtless, from the third quarter rns...

Following the expected portfolio realisations and further rounds of funding of
portfolio companies, the company intends to raise further funds for investment
in the portfolio though an equity issue of up to approximately £8m early in the
New Year. Our principal shareholder, Catella AG, has indicated to the board that it would subscribe £4m in such an issue.'

nick, i dont think that the management want to let go of this, and as long as they have the support of catella they dont have to. i always thought they might take it back private though.

[nick2412] 17/2/2004 15:11

Interesting stock this and the funding issue is interesting as is the bid speculation.

Haven't seen many prospective names in relation to a takeover and the sector is pretty small in the UK. I can only think of BTG and Medical Marketing. BTG look like they have their own issues to deal with and on that basis perhaps Medical Marketing are the predator. That would be my best guess. Of course if there remain interested parties they could come also be unlisted or from overseas. Results are soon so perhaps there will be further clues or specific details then.

[shirtless dan] 17/2/2004 14:55

"We know catella will take up their 49%".... can you explain, perhaps I missed that.

[rambutan2] 17/2/2004 12:51

would make sense. the classic one-two. some upbeat news followed by a fund raising at a big discount. we know that catella will take up their 49%, wonder how they are going to sort out the rest. be interesting to see who they can drag in.

[games] 17/2/2004 11:32

maybe the small matter of raising cash. most rise prior to announcement.